← Eichor
Condition: Elranatamab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Elranatamab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequenti
Phase 2 · 11 location(s) · SCRI Development Innovations, LLC · NCT06974786Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Phase 2 · 2 location(s) · Thomas Lund · NCT06015542A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · 90 location(s) · Pfizer · NCT05020236Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Phase 2 · 25 location(s) · Stichting European Myeloma Network · NCT06183489Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · University of California, San Diego · NCT06711705A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combi
Phase 1 · 19 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06121843A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide
Phase 1/Phase 2 · 22 location(s) · Celgene · NCT06988488Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Phase 4 · 33 location(s) · Pfizer · NCT06057402A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relap
Phase 1 · 43 location(s) · Pfizer · NCT06215118Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/Phase 2 · 7 location(s) · YOUNGIL KOH · NCT06645678A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myelom
Phase 1 · 20 location(s) · C4 Therapeutics, Inc. · NCT07280013Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Mu
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06207799A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratum
Phase 3 · 127 location(s) · Pfizer · NCT05623020ELISA in Relapsed/Refractory MM
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT06832865Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Phase 1/Phase 2 · 1 location(s) · Brigham and Women's Hospital · NCT06569147Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06483100ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
Phase 2 · 1 location(s) · University of Miami · NCT06997081MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha
Phase 3 · 271 location(s) · Pfizer · NCT06152575Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in T
Phase 3 · 64 location(s) · Intergroupe Francophone du Myelome · NCT06918002A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07454382The Norwegian Immunotherapy in Multiple Myeloma Study
Phase N/A · 23 location(s) · St. Olavs Hospital · NCT06855121Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06920251Elranatamab in R/R Multiple Myeloma
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT06138275Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 6 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06421675A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Partic
Phase 1 · 14 location(s) · Genentech, Inc. · NCT05927571A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Mye
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07382739Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06947083A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in
Phase 1 · 2 location(s) · David Avigan · NCT06799026
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.